Lonza to divest specialty ingredients business to Bain Capital and Cinven for $6.2 bil

Felicia Tan
Felicia Tan2/9/2021 8:46 AM GMT+08  • 1 min read
Lonza to divest specialty ingredients business to Bain Capital and Cinven for $6.2 bil
The transaction is expected to close in 2H2021.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Swiss pharmaceutical company Lonza has, on Feb 9, signed an agreement with private equity bidders Bain Capital and Cinven to divest its Specialty Ingredients business and operations for an enterprise value of CHF4.2 billion ($6.22 billion).

Lonza’s Specialty Ingredients business is a leading provider of microbial control solutions for professional hygiene and personal care products, which operates across 17 manufacturing sites globally.

It also offers the custom development and manufacturing of specialty chemicals and composites to support the electronics, aerospace, food and agrochemical industries.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.